Investigational Drug Information for BIIB074
✉ Email this page to a colleague
What is the development status for investigational drug BIIB074?
BIIB074 is an investigational drug.
There have been 18 clinical trials for BIIB074.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 19th 2023.
The most common disease conditions in clinical trials are Neuralgia, Trigeminal Neuralgia, and Bipolar Disorder. The leading clinical trial sponsors are Biogen, GlaxoSmithKline, and Convergence Pharmaceuticals.
There are fifteen US patents protecting this investigational drug and one hundred and ninety-eight international patents.
Summary for BIIB074
| US Patents | 15 |
| International Patents | 198 |
| US Patent Applications | 31 |
| WIPO Patent Applications | 22 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2023-04-19) |
| Vendors | 38 |
Recent Clinical Trials for BIIB074
| Title | Sponsor | Phase |
|---|---|---|
| 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Biogen | Phase 3 |
| 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Biogen | Phase 3 |
| Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy | Biogen | Phase 1 |
Clinical Trial Summary for BIIB074
Top disease conditions for BIIB074
Top clinical trial sponsors for BIIB074
US Patents for BIIB074
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BIIB074 | ⤷ Try a Trial | Erythromelalgia treatment | Convergence Pharmaceuticals Limited (Maidenhead, GB) | ⤷ Try a Trial |
| BIIB074 | ⤷ Try a Trial | Process for preparing alpha-carboxamide pyrrolidine derivatives | Convergence Pharmaceuticals Limited (GB) | ⤷ Try a Trial |
| BIIB074 | ⤷ Try a Trial | Compounds | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Try a Trial |
| BIIB074 | ⤷ Try a Trial | Compounds | Convergence Pharmaceuticals Limited (London, GB) | ⤷ Try a Trial |
| BIIB074 | ⤷ Try a Trial | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-- 3S-yl-) | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Try a Trial |
| BIIB074 | ⤷ Try a Trial | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (London, GB) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BIIB074
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BIIB074 | Cyprus | CY1122418 | 2034-10-03 | ⤷ Try a Trial |
| BIIB074 | Denmark | DK3200783 | 2034-10-03 | ⤷ Try a Trial |
| BIIB074 | European Patent Office | EP3200783 | 2034-10-03 | ⤷ Try a Trial |
| BIIB074 | Spain | ES2751688 | 2034-10-03 | ⤷ Try a Trial |
| BIIB074 | United Kingdom | GB201417497 | 2034-10-03 | ⤷ Try a Trial |
| BIIB074 | Croatia | HRP20191434 | 2034-10-03 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
